Building the next generation of biotech ventures

Welcome to BaseLaunch

We partner with scientists and entrepreneurs to help launch and grow exceptional biotech ventures developing cutting-edge therapeutics. And we know how to do this – so far our portfolio has raised over $1 billion in financing.

Money dollar Icon png

Up to CHF500,000
in financing

Access to our partners,
global biopharma & investors

Company & team
build out

Access to labs &
related infrastructure
where needed

Partners

We are very pleased to continue our commitment to BaseLaunch. Basel has always been home to great ideas and innovation and today it is a leading life sciences hub within Switzerland and globally.

James SabryGlobal Head of Roche Pharma Partnering

We are delighted to join BaseLaunch as a partner in the next phase of its company building activities. The Pureos team worked closely with BaseLaunch during the Series A funding of Alentis Therapeutics and has been very impressed by the team and the quality of the selected programs.

Klaus Breiner, PhDManaging Partner at Pureos Bioventures

This partnership will help us identify and build relationships with potential external collaborators from throughout Europe…

Dr. Adrian ZuercherVice President, Research Europe and Head of Plasma Protein Research, CSL Behring

Incubators and accelerators are central to the global healthcare start-up ecosystem. We have been collaborating with BaseLaunch since launch in supporting the growth and development of early-stage biotech ventures and recognize the contribution the team has made towards achieving their goals...

Nerida ScottHead, Johnson & Johnson Innovation

With our involvement in the review process and funding decisions through our investment board seat, we aim to contribute to BaseLaunch‘s company creation track record and leverage AbbVie‘s expertise in translating innovative science into novel therapeutics.

Christian SchubertVice President and Head of AbbVie Ventures, Cambridge, MA

Our partnership with BaseLaunch strengthens our connection to European biotech innovation. By joining the investment board, we can help guide company creation and apply Takeda’s expertise in turning science into new therapies. We look forward to participating in BaseLaunch and advancing innovative medicines together.

Alison HandleyHead of the Center for External Innovation at Takeda

Latest news

Looking for an experienced R&D leader to join a liver disease biotech as CSO

Looking for an experienced R&D leader to join a liver disease biotech as CSO

CSO Opportunity – Entrepreneurial R&D Leader for a Liver Disease-focused Biotech The company is seeking an entrepreneurial and experienced biopharma R&D leader to join an exciting…
BaseLaunch Summer Get-Together 2026

BaseLaunch Summer Get-Together 2026

Our annual summer get-together once again brought together a vibrant mix of people from across the life sciences scene in Basel and beyond. The evening…
Cancentus joins BaseLaunch portfolio

Cancentus joins BaseLaunch portfolio

We’re excited to have Cancentus join our portfolio. Cancentus, a spin-off from the University of Geneva and the University of Basel, is exploiting oncogene-induced DNA…
Lonza renews partnership with BaseLaunch

Lonza renews partnership with BaseLaunch

Building on a strong collaboration, Lonza and BaseLaunch have renewed their partnership to further support the development of innovative therapeutics. As a Domain Partner, Lonza…
Anaveon Appoints Thaminda Ramanayake as CEO

Anaveon Appoints Thaminda Ramanayake as CEO

Basel, Switzerland, March 23, 2026 – Anaveon, a late-stage preclinical biotech focused on reprogramming the immune system with precision biologics, announces today the appointment of…
Vossius renews partnership with BaseLaunch

Vossius renews partnership with BaseLaunch

We are delighted to announce that Vossius is continuing its partnership with BaseLaunch to support cutting-edge early-stage biotechs in protecting and strengthening their innovations, helping…

Application cycle is now open!

The next deadline is 4th of September 2026